ATLANTA, June 16, 2014 /PRNewswire/ -- Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, announces positive feedback on two New Drug Applications (NDA) with projected approvals of late 2016 and early 2017. Based on the feedback from the Food and Drug Administration (FDA) Avion will be moving into Phase II/III on one NDA Program, and into Phase II on the other. In line with Avion's strategic corporate mission, both NDAs are in the women's health category.
"We are very excited about the feedback from the FDA and the unique therapeutic benefits that these new products will be able to provide to our patients," stated Mark Pugh, CEO of Avion Pharmaceuticals. "Avion continues to diligently pursue product opportunities that are targeted to improve the health and well-being of women and babies. The positive news on the progress of these two NDAs will allow us to continue to work toward achieving our business goals."
"Avion's strategy of continuing to work with the best consultants, clinical research organizations, and manufacturers, clearly provides Research and Development the ability to support corporate goals and provide our customers with unique products," stated Allen Fields, VP, Head of Research and Development.
About Avion Pharmaceuticals, LLC.
Avion Pharmaceuticals, LLC., is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative products in the Women's Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.
SOURCE Avion Pharmaceuticals, LLC